Drug reference

Glycopyrronium bromide

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 282

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Maintenance treatment of chronic obstructive pulmonary disease ▶BY INHALATION OF POWDER ▶Adult: 1 capsule once daily DOSE EQUIVALENCE AND CONVERSION ▶Each capsule delivers 55 micrograms of glycopyrronium bromide (equivalent to 44 micrograms of glycopyrronium).

PDF page 282

Cautions

Arrhythmia (excluding chronic stable atrial ﬁbrillation). history of myocardial infarction. history of QT-interval prolongation. left ventricular failure. unstable ischaemic heart disease

PDF page 282

Safety

Interactions

→Appendix 1: glycopyrronium

PDF page 282

Side Effects

▶Common or very common Increased risk of infection. insomnia. pain ▶Uncommon Asthenia. cystitis. dental caries. dyspepsia. epistaxis. hyperglycaemia. hypersensitivity. numbness. respiratory disorders. throat irritation

PDF page 282

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk.

PDF page 282

Breast Feeding

Manufacturer advises use only if potential beneﬁt outweighs risk.

PDF page 282

Renal Impairment

Manufacturer advises use only if potential beneﬁt outweighs risk if eGFR less than 30 mL/minute/1.73 m2.

PDF page 282

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Inhalation powder ▶Seebri Breezhaler (Novartis Pharmaceuticals UK Ltd) Glycopyrronium bromide 55 microgram Seebri Breezhaler 44microgram inhalation powder capsules with device | 10 capsule P £9.17 | 30 capsule P £27.50 DT = £27.50 Combinations available: Beclometasone with formoterol and glycopyrronium, p. 273

PDF page 282

Clinical care

Patient And Carer Advice

Patients or carers should be given advice on appropriate inhaler technique.

PDF page 282

Dose text by age group

Adult

1 capsule once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 282

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Glycopyrronium bromide

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 282

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 282

Cautions

Arrhythmia (excluding chronic stable atrial ﬁbrillation). history of myocardial infarction. history of QT-interval prolongation. left ventricular failure. unstable ischaemic heart disease

PDF page 282

Safety

Interactions

→Appendix 1: glycopyrronium

PDF page 282

Side Effects

PDF page 282

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk.

PDF page 282

Breast Feeding

Manufacturer advises use only if potential beneﬁt outweighs risk.

PDF page 282

Renal Impairment

Manufacturer advises use only if potential beneﬁt outweighs risk if eGFR less than 30 mL/minute/1.73 m2.

PDF page 282

Dose and formulations

Medicinal Forms

PDF page 282

Clinical care

Patient And Carer Advice

Patients or carers should be given advice on appropriate inhaler technique.

PDF page 282

Dose text by age group

Adult

1 capsule once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 282

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.